Frequently Asked Questions

If you have questions about Rejoyn, you've come to the right place. Below you will find answers to common questions about Rejoyn.

Call 999 or go to the nearest Accident and Emergency department if you are experiencing a medical emergency or you are in immediate danger of suicide.

If you have any questions about your depression, please contact your healthcare professional or call 111.

References

  1. Rothman B et al. Presented at the Psych Congress 2024 Annual Meeting. 29 October – 02 November 2024, Boston, MA, USA. Poster 185.

Date of preparation: June 2025 | UK-152-2500019 (v1.0)

Intended Use

Rejoyn is a digital therapeutic intended for the treatment of depressive disorder episodes in adults. It is intended to be used alongside usual care and supported by a Healthcare Professional.
Please read the Instructions For Use for Rejoyn.

Adverse Events

Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. To report Rejoyn side effects or quality complaints, contact +44 (0) 808 168 6726 or OPUKSafety@otsuka.co.uk


Otsuka

This webpage is for the general public with an interest in Rejoyn, an app developed by Otsuka Pharmaceutical Europe Ltd.
Please note that Rejoyn requires a prescription or referral from a healthcare professional.

Date of preparation: June 2025
UK-152-2500021 (v1.0)

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.